EP
PerMed funded Projects |
3D-Leuko-TAD
Topologically
Associating Domains (TADs) boundary disruption and 3D
genome alterations as targets in acute leukemia
therapies
The
“3D-Leuko-TAD” project aims to improve treatments for
acute leukemias (acute lymphoblastic and myeloid
leukemia) by focusing on how changes in tridimensional
structures impact the development of the disease.
Read
more |
BATMAN
BOB1
as a therapeutic target and biomarker of autoimmunity to
lymphoma progression
The
BATMAN project aims to elucidate the role of BOB1 in the
progression from autoimmune SjD to lymphoma. By
utilizing patient samples, in vitro and in vivo
experimental models, novel selective BOB1 inhibitors and
radiotracers based on these inhibitors, and advanced
imaging techniques, the BATMAN consortium will
investigate the mechanisms by which BOB1 contributes to
disease progression.
Read
more |
BEATKCNQ
Validating
in silico, in vitro, and in vivo BiomarkErs for
personAlized Treatment in KCNQ2/3 encephalopathy
The
BEATKCNQ project is working to improve outcomes for
children with these disorders through the facilitation
of precision medicine.
Read
more |
BIOREXIA
Advancing
Personalised Medicine for Anorexia Nervosa: A companion
Biomarker-Target Approach
The
BIOREXIA project, a groundbreaking international
collaboration, aims to revolutionize anorexia nervosa
care by identifying and validating biomarkers to guide
personalized treatments.
Read
more |
CLL-OUTCOME
Chronic
lymphocytic leukemia: Improving survival and quality of
life
In
CLL-OUTCOME, we aim to improve survival and health
related quality of life (hrQoL) for patients with CLL;
specifically, to increase treatment efficacy of targeted
therapies and to reduce adverse events.
Read
more |
ColoStem-applied
Setting
up and validating new strategies for the identification
and eradication of the poor prognosis fetal-type
colorectal tumors
Within
this project, we will use fresh tumor tissues and PDOs
and different OMIC strategies to identify candidate
therapeutic targets for treating patients with
fetal-type tumors. Integration of the data obtained from
these analyses will allow the design of an in vitro
medium throughput screening platform to validate the
vulnerabilities of fetal-type tumors, which will be
further confirmed in zebrafish avatars and murine PDX
models.
Read
more |
COMBAT-PDAC
COMBinATorial
Personalized Approaches for Subtyping and Targeting
Functional Heterogeneity in Pancreatic Ductal
AdenoCarcinoma
The
COMBAT-PDAC project aims to address this gap by focusing
on understanding and targeting the whole spectrum of
heterogeneous pancreatic cancer cells present in
individual tumors. By combining several advanced
methods, such as in-depth genetic analysis, data-driven
insights, and innovative therapies including engineered
antibodies and engineered T lymphocytes (CAR-T cells),
COMBAT-PDAC seeks to find ways to effectively target the
many types of cells within a single tumor.
Read
more |
COMPACT
From
Understanding Complement Activation to Personalizing
Complement-Mediated Therapies in Cancer
Our
project addresses the challenge of understanding
complement activation in cancer aiming: 1) to elucidate
the role of the innate immune complement system as a
therapeutic target in cancer by creating a comprehensive
atlas of complement activation patterns in lung cancer
(both adenocarcinoma and squamous cell carcinoma) and
head and neck squamous cell carcinoma, two cancer types
in which complement seems to be activated by distinct
mechanisms, 2) to test treatment strategies in
pre-clinical human models of these cancer types, and 3)
to identify companion biomarkers to stratify patients
for inclusion in a future clinical trial for complement
targeting in cancer patients.
Read
more |
DYNAMITE
Targeting
Transcription Factor Dynamics for Personalized Therapy
in Ovarian Cancer
DYNAMITE
aims to uncover the molecular mechanisms explaining why
ovarian cancer cells become resistant to chemotherapy.
The hypothesis is that specific cellular states,
controlled by certain transcription factors (proteins
that influence gene activity), can drive this
resistance. By understanding these factors, DYNAMITE
seeks to find new, personalized treatment targets.
Read
more |
EU-Calprotect
Calprotectin
as a new companion biomarker and associated drug target
for premature vascular aging in chronic kidney disease
and type 2 diabetes
The
EU-Calprotect project is designed to advance the use of
calprotectin in clinical settings, positioning it as a
biomarker that could be paired with targeted therapies
to slow down premature vascular aging. The potential
impact of the EU-Calprotect project is substantial, as
it may pave the way for a more tailored approach to
managing cardiovascular risk in patients with CKD and
T2D.
Read
more |
GALActIC
Galectin-3
targeted antifungal prophylaxis in ICU influenza
Influenza-associated
pulmonary aspergillosis (IAPA) occurs as a complication
in up to 20% of critically ill influenza patients and is
associated with a mortality rate of 50%, twice as high
as in influenza-only patients. Diagnosing IAPA is
difficult, resulting in delayed initiation of antifungal
therapy and increased mortality. Hence, rapid
identification of patients at risk for IAPA is urgently
needed to allow patient stratification for personalized
antifungal prophylaxis.
Read
more |
GEPARD-2
Genomics-
and biomarkers-based tools for personalized treatment to
reduce chemotherapy burden in pediatric leukemia
This
study will be a transnational, multidisciplinary effort,
integrating modern multi-omics analyses of patient
samples and preclinical models with the development of
novel AI-based tools and innovative high-throughput drug
screens. These pioneering efforts aim to advance
personalized treatment strategies in early phase
clinical trials. The analysis workflows developed in
this study will have broader applicability across a wide
range of genetically-based diseases, extending beyond
the pediatric leukemias being investigated.
Read
more |
Hi-ROC
Targeting
hypoxia with heavy ions to gain control of
radioresistant cancers
The
collaborative transnational project focuses on
establishing a multimodal comprehensive non-invasive
biomarker for identifying hypoxia (a character of
malignant growing solid tumours) to personalize
radiation treatment.
Read
more |
ImmuneT-ME
Interrogation
of the immune-microenvironment of T-cell
malignancies
Our
interdisciplinary ‘ImmuneT-ME’ consortium of cancer
biologists, clinical hematologists, immunologists,
biocomputational scientists as well as EU-wide
professional and patient organizations capitalizes on
unique resources such as clinical-registry linked sample
repositories, in-silico machine learning tools, new
high-fidelity mouse models, and advocacy networks. We
propose that a comprehensive understanding of the MaTCL
immune TME will facilitate the development of new
prognostic biomarkers and personalized therapies.
Read
more |
MediMENT
Computational
drug repurposing for mental disorders using
population-wide Electronic Health Records and
Biobanks
Our
goal is to find existing medications that could be
repurposed to treat mental health disorders. We plan to
achieve this by using advanced computer-based methods to
analyze real-world data from large health registers and
biobanks in the Nordic countries. To make treatments
more tailored to each individual, we will incorporate
biomarkers—biological indicators that can help
distinguish different patient profiles.
Read
more |
MedinAD
Medin
as a cause of Aß amyloidosis in the cerebrovasculature:
Towards a treatment and biofluid marker of amyloid
angiopathy in Alzheimer’s Disease
Our
research recently revealed that the protein medin is
only found in vascular Aβ aggregates (i.e. CAA); that
removing medin significantly reduces CAA in mouse
models; and that levels of the medin precursor protein,
MFG-E8, are lower in the cerebrospinal fluid (CSF) of a
subgroup of AD patients with vascular pathology. This
suggests that medin could be a new target for treatment
and a diagnostic biomarker for CAA, but we need to study
this further.
Read
more |
MetaboTargetAML
Exploiting
patient-specific metabolic vulnerabilities in acute
myeloid leukemia
The
MetaboTargetAML consortium will generate, based on
existing and novel data and by making use of AI-driven
models, the first longitudinal metabolome roadmap at the
single cell and spatial level of AML, providing insights
into clonal dynamics, immune landscapes and metabolic
states of specific cell populations in response to
standard-of-care and novel targeted treatments. We aim
to identify novel (metabolic) candidates that can be
utilized as therapeutic targets and/or biomarkers in
routine diagnostics spectral flow pipelines for disease
prediction and patient stratification.
Read
more |
PerCareGlio
Validating
diagnostic OMICS tools for target identification and
recurrence monitoring in glioblastoma
The
project PerCareGlio builds on these findings, and we
will determine close-to-surgery patient-specific GB
(phospho-)proteomes of tumours to be integrated with
data analysis aimed to identify suitable drug targets in
addition to the standard therapy regimen.
Read
more |
PerFert
Personalisation
of Treatment for Female Infertility and Recurrent
Pregnancy Loss of Unknown Ethiology
Shared
etiological factors such as hormonal imbalances, uterine
abnormalities, inflammatory and immunological
intricacies may contribute to both uIF and uRPL, while
recent collaborative efforts have identified a range of
potential biomarkers related to those conditions. In
this study, distinctive biomarker sets will be discerned
for uIF and uRPL groups in comparison to healthy fertile
women, and subtype-specific risk assessment tools and
stratification strategies will be developed, which may
lead to identification of personalized treatment targets
for the determined pathogenetic subtypes.
Read
more |
PerMel-AI
Utilizing
AI and large-scale biobanking for drug target and
biomarker validation in personalized melanoma
treatment
The
PerMel-AI project seeks to transform melanoma treatment,
the most dangerous type of skin cancer, by using the
Human Melanoma Proteome Atlas (HMPA) along with AI and
machine learning. Our team of experts is focused on
validating new drug targets and biomarkers to create
personalized treatments.
Read
more |
PERSONALISE-DKD
Personalised
SGLT2i treatment in diabetic kidney disease supported by
multiparametric renal magnetic resonance imaging
PERSONALISE-DKD
addresses unmet needs with an international,
multidisciplinary and intersectoral project that will
identify early mechanisms and predictors of
nephroprotection by SGLT2i in DKD using MRI biomarkers
for personalised medicine.
Read
more |
PROMISE
Precision
Immunology: Mining Inborn Errors of Immunity for
Personalized Therapeutic Strategies in Non-monogenic
Inflammatory Disorders
The
goal of PROMISE is to extend these approaches to
patients with non-monogenic, genetically complex chronic
inflammatory and autoimmune disease. Patients will be
categorized based on comprehensive omics signatures,
using monogenic patients as a reference. Based on
biological similarity of the multi-omics data,
personalized treatments through mechanism-based
repurposing of immune-modulating drugs will be
introduced to patients with complex immune-mediated
inflammatory conditions.
Read
more |
SARCOTAC
Sacromeric
proteins directed PROTACs as a personalized approach in
Hypertrophic cardiomyopathy
Our
research aims to provide a first-of-its-kind therapy for
TRIM63-related HCM. If successful, this approach could
improve heart health, reduce life-threatening
complications, and serve as a model for treating other
genetic heart diseases, offering hope to patients who
currently lack effective treatments.
Read
more |
SEI-MITO
Speed
the Efficacy of Idebenone on MITOchondrial Leber
Hereditary Optic Neuropathy (LHON) targeting NQO1
We
aim at testing therapeutic efficacy of FAD and its
precursor, alone and in combination with NQO1 inducers,
on LHON cell models carrying the two NQO1 polymorphic
variants hampering idebenone efficacy. By increasing
NQO1 expression and protein stability we expect to
improve idebenone efficacy on rescuing the mitochondrial
energetic defect. We will then test the NQO1 “enhancer
therapy” in vivo, in a selected group of chronic LHON
patients carrying the NQO1 polymorphic variants.
Read
more |
SURPASS-TNBC
Modeling
early anti-tumor immune SURveillance Pathways and
resistAnce mechanism for perSonaliSed treatment and
innovation in Triple Negative Breast Cancers
The
objectives of the SURPASS-TNBC project are: 1) to
validate biomarkers allowing before treatment to
identify patients that will not benefit from the
treatment, 2) discover and validate alternative targets
to be evaluated in resistant TNBC patients.
Read
more |
TAP-GRIN
Tailored
Approaches targeting Pathophysiology in GRIN-related
neurodevelopmental disorders
The
main objective of the study is to validate GRIN LoF
variants as targets for treatment with L-serine. We aim
to demonstrate that L-serine improves neurodevelopmental
outcomes in children and young adults with GRIN-NDD. We
will determine global clinical improvements along with
changes in cognitive and motor function, behaviour,
sleep, and seizures.
Read
more |
UNMASK
UNveiling
the pathobiology of Metabolic dysfunction-Associated
steatotic liver disease (MASLD) for the discovery of new
therapeutics and biomarKers
The
UNMASK project seeks to enhance understanding of MASLD
by exploring its hierarchical mechanisms. A primary goal
is to develop a portfolio of non-invasive biomarkers to
improve MASLD diagnosis and patient classification and
stratification.
Read
more |
|
See
all
projects |
